10x Genomics (TXG)
(Real Time Quote from BATS)
$17.23 USD
-0.26 (-1.49%)
Updated Jul 15, 2024 02:01 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
TXG 17.23 -0.26(-1.49%)
Will TXG be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TXG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TXG
10x Genomics (TXG) Surges 8.2%: Is This an Indication of Further Gains?
International Markets and 10x Genomics (TXG): A Deep Dive for Investors
TXG: What are Zacks experts saying now?
Zacks Private Portfolio Services
10x Genomics (TXG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp
3 Medical Products Stocks Set to Beat This Earnings Season
Other News for TXG
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024
Cathie Wood's ARK Investment buys 283K shares of 10x Genomics today
10x Genomics (TXG) Gets a Buy from Barclays
10x Genomics price target lowered by $12 at Barclays, here's why
Cathie Wood’s top and bottom performing ARKK holdings of H1